Wilmslow Estates Limited disclosed that they own 13.1% of Histogenics Corp. (NASDAQ:HSGX) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, October 3rd. The investor owns 2,075,331 shares of the stock worth about $6,433,526. The disclosure is available through EDGAR at this hyperlink.
Separately, Sabby Management LLC increased its position in shares of Histogenics Corp. by 28.0% in the first quarter. Sabby Management LLC now owns 150,630 shares of the company’s stock worth $345,000 after buying an additional 32,965 shares in the last quarter. 38.63% of the stock is owned by institutional investors and hedge funds.
Histogenics Corp. (NASDAQ:HSGX) traded down 3.43% during trading on Monday, hitting $3.10. 80,397 shares of the stock traded hands. Histogenics Corp. has a 12 month low of $1.39 and a 12 month high of $4.97. The company’s 50 day moving average price is $3.18 and its 200 day moving average price is $2.33. The company’s market cap is $41.14 million.
Histogenics Corp. (NASDAQ:HSGX) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.01. During the same period in the previous year, the business earned ($0.58) earnings per share. On average, equities research analysts anticipate that Histogenics Corp. will post ($2.11) EPS for the current fiscal year.
A number of equities analysts have commented on the stock. William Blair downgraded shares of Histogenics Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 7th. Needham & Company LLC boosted their target price on shares of Histogenics Corp. from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, September 19th. Zacks Investment Research upgraded shares of Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a report on Friday, August 26th. Finally, BTIG Research upgraded shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 target price for the company in a report on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Histogenics Corp. presently has a consensus rating of “Buy” and a consensus target price of $7.65.
In other news, major shareholder Split Rock Partners Ii, Lp bought 276,801 shares of the stock in a transaction that occurred on Thursday, September 29th. The stock was bought at an average cost of $2.25 per share, for a total transaction of $622,802.25. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 16.80% of the company’s stock.
Histogenics Corp. Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Want to see what other hedge funds are holding HSGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Histogenics Corp. (NASDAQ:HSGX).
Receive News & Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.